Business
Mednow Acquires the License and Exclusive Canadian Distribution Rights for Genetic Testing Technology from TruDiagnostic™
Mednow Acquires the License and Exclusive Canadian Distribution Rights for Genetic Testing Technology from TruDiagnostic™.
About this update from Mednow Inc.
[{"type":"text","content":"\nMednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW; OTCQB:MDNWF), Canada’s on-demand virtual pharmacy, is pleased to announce the Company has signed a two-year investment agreement (the “Investment Agreement”) to acquire the License and Exclusive Distribution Rights of TruDiagnostic™ in Canada. Pursuant to the Investment Agreement, Mednow paid a one-time licensing fee of US$150,000 to TruDiagnostic™ for access and use of the TruDiagnostic™ Technology and TruDiagnostic™ Platform for the development, importation, use, marketing, sale and distribution of the Epigenetic Testing Kits.\n\nMednow’s strategy is to develop a digital interdisciplinary model of care. Anchored in pharmacy and supported by telemedicine and complementary health care services, having the exclusive distribution rights of TruDiagnostic™ in Canada will enhance Mednow’s approach to provide a full spectrum health care ecosystem. The Company intends to continue to build a holistic approach to patient care.\n\nTruDiagnostic™ TruAge Complete Collection is a comprehensive way for a patient to analyze methylation biomarkers to quantify the process of aging. Aging is the number one risk factor for most chronic diseases and death. By quantifying this process, individuals can potentially predict future diseases and treat aging as a primary objective factor. The TruAge Complete collection allows everyone to look at their aging process by providing them their biological age, their immune age, and telomere length. It also includes the Dunedin Pace of Aging analysis, developed by Duke University. The Dunedin Pace of Aging analysis is the only publicly available aging algorithm trained on phenotypes and variables of health, rather than chronological age. We also offer analysis and reporting for other health and age-related biomarkers such as ability to lose weight with caloric restriction, immune cell subsets, and more.\n\nIn the first quarter of 2022, it is anticipated that Mednow’s patients will be able to: order the test on its website, have their blood specimen taken, and shipped back to the lab for testing and diagnosis. This agreement between Mednow and TruDiagnostic™ aligns with Mednow’s approach to provide a wide array of services on our easy-to-use Mednow digit...